Document is current
Any future updates will be listed below
-
Authors
Kamiya, Hajime
Kobayashi, Shin https://orcid.org/0000-0001-9321-8452
Kudo, Masashi
Sugimoto, Motokazu
Kawazoe, Akihito
Bando, Hideaki
Tsukada, Yuichiro
Ito, Masaaki
Yoshino, Takayuki
Gotohda, Naoto
-
Funding
Funding for this research was provided by:
National Cancer Center Research and Development Fund ((2024-A-05))
- License Information
-
More Information
Article History
Received: 21 July 2025
Accepted: 10 November 2025
First Online: 21 November 2025
Declarations
:
: The authors declare that there are no direct competing interests related to this study. However, potential indirect competing interests may exist through that relationship. Here is that list: TY received honoraria from Chugai, Takeda, Merck Biopharma, Ono and MSD; consulting fee from Sumitomo Corp. and Indivumed. TY received research funding from Amgen, Bristol-Myers Squibb, Caris MPI, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Exact Sciences, FALCO Biosystems, Medical & Biological Laboratories, Merus N.V., Miyarisan Pharmaceutical, Molecular Health GmbH, MSD, Natera Inc., Nippon Boehringer Ingelheim, Ono Pharmaceutical, Pfizer Japan, Roche Diagnostics, Sanofi, Sysmex, Taiho Pharmaceutical, and Takeda Pharmaceutical. The other authors have no competing interests to declare.
: This study was institutionally approved by the National Cancer Center East Hospital (Registration No. 2017-483).
